Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers

Published:2013-08-05 Issue:19 Volume:73 Page:6013-6023
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Garrett Joan T.,Sutton Cammie R.,Kurupi Richard,Bialucha Carl Uli,Ettenberg Seth A.,Collins Scott D.,Sheng Qing,Wallweber Jerry,DeFazio-Eli Lisa,Arteaga Carlos L.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance;Cancer Letters;2024-09

2. HER3 receptor and its role in the therapeutic management of metastatic breast cancer;Journal of Translational Medicine;2024-07-17

3. The effects of ARID1A mutation in gastric cancer and its significance for treatment;Cancer Cell International;2023-11-26

4. Role of human epidermal growth factor receptor 3 in treatment resistance of anaplastic lymphoma kinase translocated non-small cell lung cancer;Cancer Biology & Therapy;2023-09-18

5. Inhibiting HER3 Hyperphosphorylation in HER2‐Overexpressing Breast Cancer through Multimodal Therapy with Branched Gold Nanoshells;Small;2023-08-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP